Kidist K Yimam, MD
Internal Medicine · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · California Pacific Medical Center- Van Ness Campus · Sutter Auburn Faith Hospital · Sutter Medical Center, Sacramento · Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Yimam’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A103412 · Current
Licensed to practise in California · since 2008 · expires 2028-02-29 · University of Nevada School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Sutter Auburn Faith HospitalAuburn, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Auburn Faith Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2.01) · 312 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.62 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 160.66 (100.73 to 220.58) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16 · 241 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,272 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,484 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.5) · 2,442 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.11 (1.72 to 6.49) · 442 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.12 (0.47 to 3.78) · 417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.72 (0.67 to 18.77) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.26 (4.11 to 12.4) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.18) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.3) · 1,845 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 34 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.9 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -30.1 · 250 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.5) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8 to 16.4) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 95 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9 to 15.2) · 1,787 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 473 cases | No different | Jan 2024 – Dec 2024 |
What patients said (563 patients answered, 27% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 81% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 81% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$74,013
Medicare paid this office $74,013 for 277 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $19,732 | $106 |
| Return visit (30+ min) | 97 | $14,465 | $106 |
| Long return visit (40+ min) | 49 | $10,657 | $154 |
| Long return visit (40+ min) | 45 | $6,529 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,082 | $154 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $19,732 | $106 |
| Return visit (30+ min) | 97 | $14,465 | $106 |
| Long return visit (40+ min) | 49 | $10,657 | $154 |
| Long return visit (40+ min) | 45 | $6,529 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,082 | $154 |
| Return visit (30+ min) | 36 | $3,707 | $79 |
| New patient visit (60+ min) | 15 | $2,877 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,895 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,501 | $115 |
| Short return visit (20+ min) | 19 | $1,448 | $76 |
| Measurement of liver stiffness | 50 | $1,415 | $27 |
Procedures Medicare counted
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
277 Original Medicare patients in 2024. Average age 69 · Under 65 20% · 85 and older 4% · Women 57% · Also on Medicaid 42% · Health risk score 2.29. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Chronic kidney disease 49% · Diabetes 44% · Coronary heart disease 26% · Depression 25% · Atrial fibrillation 19% · Heart failure 17% · COPD 14% · Cancer 12% · Dementia 8%.
The office billed $295,956, Medicare allowed $95,994 and paid $74,013; for 692 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 277 | 692 | 69 | 2.29 | $295,956 | $74,013 |
| 2023 | 242 | 594 | 67 | 2.34 | $269,265 | $64,844 |
| 2022 | 239 | 599 | 69 | 2.44 | $279,265 | $65,340 |
| 2021 | 249 | 656 | 68 | 2.71 | $277,792 | $72,229 |
| 2020 | 289 | 791 | 68 | 2.75 | $367,335 | $80,583 |
| 2019 | 255 | 570 | 68 | 2.62 | $278,634 | $59,724 |
| 2018 | 262 | 614 | 68 | 2.59 | $313,391 | $60,007 |
| 2017 | 207 | 568 | 67 | 2.61 | $273,829 | $53,977 |
| 2016 | 232 | 587 | 66 | 2.53 | $300,970 | $58,444 |
| 2015 | 200 | 533 | 65 | 2.89 | $280,866 | $60,658 |
| 2014 | 83 | 128 | 67 | 2.42 | $61,799 | $14,916 |
| 2013 | 61 | 101 | 75 | 2.36 | $34,616 | $9,147 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $14,230 | $106 |
| Long return visit (40+ min) | 69 | $13,774 | $141 |
| Long return visit (40+ min) | 42 | $8,986 | $127 |
| Return visit (30+ min) | 55 | $6,596 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,733 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,461 | $157 |
| New patient visit (60+ min) | 15 | $2,660 | $177 |
| Return visit (30+ min) | 26 | $2,364 | $76 |
| Measurement of liver stiffness | 43 | $1,134 | $26 |
2022: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $16,204 | $91 |
| Long return visit (40+ min) | 58 | $12,097 | $139 |
| Long return visit (40+ min) | 50 | $9,339 | $130 |
| Return visit (30+ min) | 41 | $5,375 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,900 | $169 |
| New patient visit (60+ min) | 21 | $3,765 | $179 |
| Return visit (30+ min) | 33 | $3,494 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,606 | $64 |
| Measurement of liver stiffness | 24 | $650 | $27 |
2021: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $13,966 | $93 |
| Long return visit (40+ min) | 62 | $13,049 | $150 |
| Long return visit (40+ min) | 50 | $10,271 | $128 |
| Return visit (30+ min) | 76 | $9,427 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,068 | $181 |
| Return visit (30+ min) | 45 | $4,442 | $78 |
| New patient visit (60+ min) | 16 | $2,844 | $178 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,115 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,884 | $65 |
| Short return visit (20+ min) | 18 | $1,474 | $70 |
| Measurement of liver stiffness | 17 | $458 | $27 |
2020: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $16,517 | $95 |
| Long return visit (40+ min) | 87 | $15,589 | $115 |
| Long return visit (40+ min) | 59 | $9,861 | $100 |
| Return visit (30+ min) | 67 | $7,451 | $89 |
| Critical care, first 30-74 minutes | 13 | $6,213 | $200 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,811 | $185 |
| New patient visit (60+ min) | 25 | $4,369 | $175 |
| Return visit (30+ min) | 45 | $3,942 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,311 | $66 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $2,049 | $93 |
| Measurement of liver stiffness | 19 | $577 | $30 |
| Short return visit (20+ min) | 12 | $515 | $43 |
| Measurement of liver stiffness | 13 | $131 | $10 |
2019: 9 services
| Long return visit (40+ min) | 124 | $24,800 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $8,434 | $94 |
| Long return visit (40+ min) | 51 | $6,906 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $4,376 | $182 |
| New patient visit (60+ min) | 25 | $3,794 | $152 |
| Measurement of liver stiffness | 46 | $1,368 | $29 |
| Return visit (30+ min) | 13 | $1,366 | $98 |
| Return visit (30+ min) | 11 | $784 | $71 |
| Measurement of liver stiffness | 13 | $170 | $13 |
2018: 10 services
| Long return visit (40+ min) | 109 | $19,863 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $12,762 | $90 |
| Long return visit (40+ min) | 54 | $6,993 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,239 | $175 |
| New patient visit (60+ min) | 21 | $3,242 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,192 | $63 |
| Return visit (30+ min) | 15 | $1,191 | $74 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,109 | $101 |
| Measurement of liver stiffness | 21 | $579 | $26 |
| Measurement of liver stiffness | 27 | $298 | $11 |
2017: 10 services
| Long return visit (40+ min) | 87 | $16,560 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $10,855 | $90 |
| Long return visit (40+ min) | 56 | $7,693 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,386 | $175 |
| New patient visit (60+ min) | 18 | $2,913 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,630 | $63 |
| Return visit (30+ min) | 17 | $1,481 | $74 |
| Return visit (30+ min) | 19 | $1,297 | $59 |
| Measurement of liver stiffness | 13 | $388 | $30 |
| Measurement of liver stiffness | 23 | $255 | $11 |
2016: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $14,880 | $91 |
| Long return visit (40+ min) | 73 | $12,848 | $106 |
| Long return visit (40+ min) | 53 | $7,397 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,045 | $178 |
| New patient visit (60+ min) | 19 | $2,993 | $158 |
| New patient visit (60+ min) | 19 | $2,677 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,395 | $63 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,251 | $114 |
| Return visit (30+ min) | 11 | $1,065 | $82 |
| Return visit (30+ min) | 13 | $898 | $60 |
| Measurement of liver stiffness | 19 | $388 | $19 |
| Measurement of liver stiffness | 12 | $127 | $11 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $17,994 | $94 |
| Long return visit (40+ min) | 64 | $11,608 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $9,476 | $182 |
| Long return visit (40+ min) | 48 | $6,805 | $99 |
| New patient visit (60+ min) | 29 | $4,624 | $159 |
| Measurement of liver stiffness | 13 | $158 | $12 |
2014: 3 services
| Long return visit (40+ min) | 43 | $5,787 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,219 | $89 |
| New patient visit (60+ min) | 18 | $3,207 | $178 |
2013: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,878 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,184 | $62 |
Medicaid work
$7,274 in 2024
Medicaid paid $7,274 for 174 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 117 | $5,536 |
| Long return visit (40+ min) | 27 | $983 |
| Return visit (30+ min) | 30 | $756 |
| 2024 | 174 | 3 | 18 | $7,274 |
| 2023 | 122 | 2 | 17 | $6,017 |
| 2022 | 144 | 2 | 19 | $6,999 |
| 2021 | 109 | 3 | 15 | $6,255 |
| 2020 | 263 | 3 | 20 | $10,953 |
| 2019 | 14 | 1 | 14 | $331 |
| 2018 | 123 | 2 | 13 | $6,221 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 72 | $3,355 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 50 | $2,661 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 107 | $5,007 |
| Long return visit (40+ min) | 37 | $1,993 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 46 | $2,878 |
| Long return visit (40+ min) | 50 | $2,567 |
| Return visit (30+ min) | 13 | $810 |
2020
| Long return visit (40+ min) | 126 | $5,328 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 123 | $5,231 |
| Return visit (30+ min) | 14 | $394 |
2019
| Long return visit (40+ min) | 14 | $331 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 86 | $4,261 |
| Long return visit (40+ min) | 37 | $1,960 |
Drugs they prescribed that Part D paid
$1,590,547
Pharmacies billed $1,590,547 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,342 generic and fewer than 11 brand-name prescriptions · $1,590,547 in drug cost · 154 antibiotic prescriptions to 35 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 122 | $423,162 | $3,469 |
| Ocaliva | 36 | $379,686 | $10,547 |
| Livdelzi | 14 | $182,060 | $13,004 |
| Vemlidy | 79 | $112,237 | $1,421 |
| Ursodiol | 336 | $71,769 | $214 |
See all 29 drugs
| Xifaxan | 122 | $423,162 | $3,469 |
| Ocaliva | 36 | $379,686 | $10,547 |
| Livdelzi | 14 | $182,060 | $13,004 |
| Vemlidy | 79 | $112,237 | $1,421 |
| Ursodiol | 336 | $71,769 | $214 |
| Tenofovir Disoproxil | 36 | $20,907 | $581 |
| Mycophenolic Acid | 57 | $19,132 | $336 |
| Entecavir | 38 | $17,451 | $459 |
| Tacrolimus | 51 | $17,293 | $339 |
| Lokelma | 11 | $14,528 | $1,321 |
| Mycophenolate Mofetil | 73 | $9,193 | $126 |
| Lactulose | 27 | $3,164 | $117 |
| Valganciclovir | 28 | $2,774 | $99 |
| Prevalite | 11 | $2,347 | $213 |
| Budesonide Ec | 14 | $2,076 | $148 |
| Azathioprine | 78 | $2,018 | $26 |
| Fenofibrate | 36 | $1,486 | $41 |
| Budesonide Dr | 14 | $1,201 | $86 |
| Pantoprazole | 88 | $811 | $9 |
| Prednisone | 100 | $799 | $8 |
| Spironolactone | 63 | $498 | $8 |
| Constulose | 17 | $465 | $27 |
| Fluconazole | 28 | $359 | $13 |
| Fenofibrate | 16 | $316 | $20 |
| Ondansetron | 12 | $256 | $21 |
| Furosemide | 72 | $241 | $3 |
| Metoprolol | 11 | $110 | $10 |
| Amlodipine Besylate | 33 | $97 | $3 |
| Doxepin | 20 | $94 | $5 |
Year by year
| 2024 | 1,716 | 204 | None | None | $1,590,547 |
| 2023 | 1,617 | 178 | None | None | $1,434,967 |
| 2022 | 1,421 | 149 | None | None | $1,320,673 |
| 2021 | 1,369 | 157 | None | 21% | $992,237 |
| 2020 | 1,373 | 137 | None | 24% | $1,353,218 |
| 2019 | 940 | 131 | None | 26% | $832,688 |
| 2018 | 859 | 110 | None | None | $1,127,693 |
| 2017 | 734 | 89 | 3% (18) | 40% | $1,223,552 |
| 2016 | 497 | 79 | 3% (15) | 42% | $1,452,783 |
| 2015 | 403 | 60 | 4% (17) | None | $2,215,947 |
| 2014 | 40 | 23 | None | 53% | $316,676 |
| 2013 | 12 | None | 0% (0) | None | $1,744 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Xifaxan | 140 | $492,602 | $3,519 |
| Ocaliva | 33 | $388,110 | $11,761 |
| Vemlidy | 66 | $100,331 | $1,520 |
| Ursodiol | 266 | $71,508 | $269 |
| Mycophenolic Acid | 59 | $25,948 | $440 |
| Tenofovir Disoproxil | 49 | $22,273 | $455 |
| Lokelma | 13 | $17,119 | $1,317 |
| Tacrolimus | 45 | $16,382 | $364 |
| Budesonide Dr | 27 | $15,796 | $585 |
| Entecavir | 48 | $14,626 | $305 |
| Mycophenolate Mofetil | 60 | $8,331 | $139 |
| Valganciclovir | 19 | $4,651 | $245 |
| Lactulose | 41 | $4,423 | $108 |
| Azathioprine | 80 | $3,916 | $49 |
| Constulose | 36 | $3,424 | $95 |
| Cyclosporine Modified | 11 | $2,178 | $198 |
| Pantoprazole | 76 | $2,001 | $26 |
| Spironolactone | 58 | $1,611 | $28 |
| Prednisone | 115 | $1,404 | $12 |
| Fenofibrate | 33 | $1,261 | $38 |
| Fluconazole | 28 | $1,028 | $37 |
| Furosemide | 62 | $564 | $9 |
| Fenofibrate | 18 | $480 | $27 |
| Amlodipine Besylate | 30 | $208 | $7 |
| Sulfamethoxazole-Trimethoprim | 37 | $148 | $4 |
2022: 21 drugs
| Xifaxan | 141 | $469,581 | $3,330 |
| Ocaliva | 28 | $284,950 | $10,177 |
| Ursodiol | 219 | $71,109 | $325 |
| Vemlidy | 45 | $69,719 | $1,549 |
| Mycophenolic Acid | 57 | $22,177 | $389 |
| Entecavir | 35 | $20,948 | $599 |
| Lokelma | 19 | $14,999 | $789 |
| Tenofovir Disoproxil | 49 | $12,560 | $256 |
| Lactulose | 58 | $8,338 | $144 |
| Tacrolimus | 22 | $4,827 | $219 |
| Azathioprine | 98 | $4,418 | $45 |
| Mycophenolate Mofetil | 38 | $3,089 | $81 |
| Fluconazole | 24 | $1,468 | $61 |
| Constulose | 23 | $1,402 | $61 |
| Prevalite | 11 | $1,232 | $112 |
| Prednisone | 125 | $1,176 | $9 |
| Spironolactone | 56 | $1,159 | $21 |
| Pantoprazole | 51 | $901 | $18 |
| Furosemide | 65 | $383 | $6 |
| Amlodipine Besylate | 37 | $235 | $6 |
| Sulfamethoxazole-Trimethoprim | 21 | $79 | $4 |
2021: 25 drugs
| Xifaxan | 127 | $369,507 | $2,910 |
| Ocaliva | 27 | $263,141 | $9,746 |
| Ursodiol | 237 | $71,688 | $302 |
| Vemlidy | 42 | $62,249 | $1,482 |
| Mycophenolic Acid | 36 | $31,607 | $878 |
| Entecavir | 46 | $27,386 | $595 |
| Lactulose | 73 | $6,408 | $88 |
| Tacrolimus | 23 | $5,556 | $242 |
| Tenofovir Disoproxil | 41 | $5,496 | $134 |
| Azathioprine | 79 | $4,509 | $57 |
| Mycophenolate Mofetil | 38 | $2,410 | $63 |
| Constulose | 37 | $1,439 | $39 |
| Budesonide Dr | 11 | $1,396 | $127 |
| Prevalite | 12 | $1,345 | $112 |
| Sps | 11 | $1,218 | $111 |
| Spironolactone | 68 | $1,200 | $18 |
| Fluconazole | 23 | $1,123 | $49 |
| Pantoprazole | 53 | $843 | $16 |
| Prednisone | 70 | $790 | $11 |
| Fenofibrate | 11 | $776 | $71 |
| Furosemide | 64 | $381 | $6 |
| Amoxicillin-Clavulanate Potass | 12 | $363 | $30 |
| Amlodipine Besylate | 29 | $192 | $7 |
| Omeprazole | 13 | $136 | $10 |
| Sulfamethoxazole-Trimethoprim | 15 | $72 | $5 |
2020: 29 drugs
| Epclusa | 19 | $496,237 | $26,118 |
| Xifaxan | 121 | $318,411 | $2,631 |
| Ocaliva | 30 | $274,075 | $9,136 |
| Vemlidy | 49 | $75,319 | $1,537 |
| Ursodiol | 192 | $67,292 | $350 |
| Mycophenolic Acid | 18 | $24,185 | $1,344 |
| Tacrolimus | 38 | $15,042 | $396 |
| Entecavir | 36 | $12,346 | $343 |
| Lactulose | 75 | $6,734 | $90 |
| Valganciclovir | 15 | $4,381 | $292 |
| Tenofovir Disoproxil | 29 | $3,883 | $134 |
| Mycophenolate Mofetil | 34 | $2,577 | $76 |
| Azathioprine | 54 | $2,544 | $47 |
| Spironolactone | 97 | $1,906 | $20 |
| Constulose | 22 | $1,461 | $66 |
| Pantoprazole | 73 | $1,142 | $16 |
| Nadolol | 20 | $1,102 | $55 |
| Fluconazole | 12 | $832 | $69 |
| Prednisone | 75 | $741 | $10 |
| Fenofibrate | 11 | $722 | $66 |
| Generlac | 11 | $628 | $57 |
| Furosemide | 80 | $347 | $4 |
| Ondansetron | 13 | $293 | $23 |
| Omeprazole | 19 | $239 | $13 |
| Famotidine | 18 | $141 | $8 |
| Amlodipine Besylate | 24 | $122 | $5 |
| Ciprofloxacin | 17 | $114 | $7 |
| Sulfamethoxazole-Trimethoprim | 18 | $84 | $5 |
| Rosuvastatin | 11 | $41 | $4 |
2019: 20 drugs
| Ocaliva | 31 | $259,172 | $8,360 |
| Xifaxan | 78 | $200,038 | $2,565 |
| Ursodiol | 131 | $52,238 | $399 |
| Vemlidy | 36 | $42,470 | $1,180 |
| Entecavir | 16 | $4,371 | $273 |
| Tenofovir Disoproxil | 17 | $3,399 | $200 |
| Tacrolimus | 28 | $3,011 | $108 |
| Azathioprine | 51 | $2,938 | $58 |
| Mycophenolate Mofetil | 28 | $2,462 | $88 |
| Lactulose | 41 | $1,756 | $43 |
| Spironolactone | 70 | $1,354 | $19 |
| Nadolol | 17 | $877 | $52 |
| Pantoprazole | 52 | $825 | $16 |
| Ciprofloxacin | 37 | $446 | $12 |
| Generlac | 15 | $435 | $29 |
| Furosemide | 76 | $358 | $5 |
| Prednisone | 28 | $314 | $11 |
| Omeprazole | 13 | $159 | $12 |
| Ondansetron | 11 | $85 | $8 |
| Metronidazole | 11 | $65 | $6 |
2018: 18 drugs
| Ocaliva | 44 | $320,485 | $7,284 |
| Xifaxan | 94 | $219,681 | $2,337 |
| Ursodiol | 123 | $38,891 | $316 |
| Vemlidy | 26 | $27,918 | $1,074 |
| Tenofovir Disoproxil | 15 | $3,327 | $222 |
| Azathioprine | 61 | $2,522 | $41 |
| Mycophenolate Mofetil | 23 | $2,409 | $105 |
| Tacrolimus | 19 | $2,328 | $123 |
| Lactulose | 41 | $1,962 | $48 |
| Spironolactone | 46 | $782 | $17 |
| Pantoprazole | 55 | $547 | $10 |
| Prednisone | 29 | $428 | $15 |
| Propranolol | 18 | $292 | $16 |
| Furosemide | 56 | $263 | $5 |
| Trazodone | 14 | $140 | $10 |
| Omeprazole | 17 | $98 | $6 |
| Ciprofloxacin | 16 | $78 | $5 |
| Metronidazole | 11 | $58 | $5 |
2017: 15 drugs
| Ocaliva | 63 | $390,531 | $6,199 |
| Harvoni | 11 | $344,343 | $31,304 |
| Xifaxan | 76 | $155,051 | $2,040 |
| Ursodiol | 92 | $30,273 | $329 |
| Viread | 29 | $29,423 | $1,015 |
| Azathioprine | 34 | $1,818 | $53 |
| Nadolol | 12 | $1,074 | $89 |
| Spironolactone | 55 | $1,043 | $19 |
| Lactulose | 17 | $956 | $56 |
| Pantoprazole | 48 | $542 | $11 |
| Prednisone | 54 | $506 | $9 |
| Nystatin | 11 | $346 | $31 |
| Furosemide | 45 | $153 | $3 |
| Omeprazole | 13 | $62 | $5 |
| Sulfamethoxazole-Trimethoprim | 20 | $42 | $2 |
2016: 14 drugs
| Harvoni | 23 | $730,539 | $31,763 |
| Xifaxan | 55 | $95,500 | $1,736 |
| Viread | 36 | $33,018 | $917 |
| Valganciclovir | 11 | $29,973 | $2,725 |
| Ursodiol | 54 | $23,269 | $431 |
| Entecavir | 16 | $6,852 | $428 |
| Ribavirin | 18 | $4,313 | $240 |
| Azathioprine | 23 | $1,467 | $64 |
| Spironolactone | 32 | $455 | $14 |
| Lactulose | 11 | $433 | $39 |
| Prednisone | 18 | $280 | $16 |
| Pantoprazole | 16 | $127 | $8 |
| Furosemide | 21 | $98 | $5 |
| Metoprolol | 12 | $37 | $3 |
2015: 12 drugs
| Harvoni | 51 | $1,611,632 | $31,601 |
| Sovaldi | 14 | $393,261 | $28,090 |
| Ursodiol | 40 | $16,309 | $408 |
| Viread | 13 | $12,282 | $945 |
| Ribavirin | 30 | $8,164 | $272 |
| Tacrolimus | 11 | $2,676 | $243 |
| Azathioprine | 12 | $1,054 | $88 |
| Spironolactone | 29 | $307 | $11 |
| Lactulose | 16 | $286 | $18 |
| Prednisone | 14 | $144 | $10 |
| Omeprazole | 13 | $113 | $9 |
| Furosemide | 19 | $76 | $4 |
Money from drug and device companies
$18,584 in 2025
| 2025 | 3 | 13 | $16,300 | $18,584 |
| 2024 | 4 | 28 | $15,452 | $18,754 |
| 2023 | 3 | 7 | $14,870 | $15,244 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Livdelzi | $18,429 | 11 payments
|
| Perspectum Diagnostics | Mrcp+ | $133 | 1 payment
|
| Ipsen Biopharmaceuticals | Bylvay | $22 | 1 payment
|
See all 13 published payments
| Gilead Sciences | Meals · 2025-11-07 | None | $137 |
| Gilead Sciences | Travel · 2025-06-11 | Livdelzi | $612 |
| Gilead Sciences | Paid to speak or teach · 2025-06-05 | Livdelzi | $3,790 |
| Gilead Sciences | Meals · 2025-06-03 | Livdelzi | $122 |
| Gilead Sciences | Travel · 2025-05-30 | Livdelzi | $438 |
| Gilead Sciences | Paid to speak or teach · 2025-05-29 | Livdelzi | $3,790 |
| Gilead Sciences | Paid to speak or teach · 2025-05-28 | Livdelzi | $3,790 |
| Gilead Sciences | Meals · 2025-05-27 | Livdelzi | $146 |
| Gilead Sciences | Travel · 2025-05-23 | Livdelzi | $555 |
| Gilead Sciences | Meals · 2025-05-20 | Livdelzi | $120 |
| Gilead Sciences | Paid to speak or teach · 2025-02-26 | Livdelzi | $4,930 |
| Perspectum Diagnostics | Meals · 2025-02-21 | Mrcp+ | $133 |
| Ipsen Biopharmaceuticals | Meals · 2025-02-03 | Bylvay | $22 |
See earlier years (2024, 2023)
2024: $18,754
| Gilead Sciences | Livdelzi | $15,034 | 24 payments
|
| Intercept Pharmaceuticals | Ocaliva | $1,890 | 1 payment
|
| Ipsen Biopharmaceuticals | Iqirvo | $1,807 | 2 payments
|
| Albireo Pharma | Iqirvo | $23 | 1 payment
|
2023: $15,244
| Intercept Pharmaceuticals | Ocaliva | $8,644 | 5 payments
|
| GlaxoSmithKline | None | $6,500 | 1 payment
|
| Gilead Sciences | None | $100 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis · 2021 | Their institution | $194,932 |
| Gilead Sciences, Inc. · A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study Intended To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (Pbc) and An Incomplete Response Or Intolerance To Ursodeoxycholic Acid (Udca) · 2025 | Their institution | $38,298 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis · 2020 | Their institution | $26,752 |
| Gilead Sciences, Inc. · An Open Label Long-Term Study To Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (Pbc) · 2024 | Their institution | $23,211 |
| Gilead Sciences, Inc. · A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study Intended To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (Pbc) and An Incomplete Response Or Intolerance To Ursodeoxycholic Acid (Udca) · 2024 | Their institution | $22,839 |
| Gilead Sciences, Inc. · An Open Label Long-Term Study To Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (Pbc) · 2025 | Their institution | $17,606 |
| Ipsen Pharma SAS · A Double-Blind, Randomized, Placebo-Controlled Study and Open-Label Long Term Extension To Evaluate the Efficacy and Safety of Elafibranor 80 Mg in Patients With Primary Biliary Cholangitis With Inadequate Response Or Intolerance To Ursodeoxycholic Acid · 2025 | Their institution | $15,571 |
| Gilead Sciences, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (Pbc) and Compensated Cirrhosis · 2025 | Their institution | $14,270 |
| Ipsen Pharma SAS · A Double-Blind, Randomized, Placebo-Controlled Study and Open-Label Long Term Extension To Evaluate the Efficacy and Safety of Elafibranor 80 Mg in Patients With Primary Biliary Cholangitis With Inadequate Response Or Intolerance To Ursodeoxycholic Acid · 2023 | Their institution | $14,158 |
| Ipsen Pharma SAS · A Double-Blind, Randomized, Placebo-Controlled Study and Open-Label Long Term Extension To Evaluate the Efficacy and Safety of Elafibranor 80 Mg in Patients With Primary Biliary Cholangitis With Inadequate Response Or Intolerance To Ursodeoxycholic Acid · 2024 | Their institution | $8,115 |
Professional record
- NPI
- 1639321839
- Licence
- CA 906368, CA A103412California A103412: Current · expires 2028-02-29
- Trained
- University of Nevada School of Medicine, 2006
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RT0003X (207RT0003X); Federal specialty code 204F00000X (204F00000X); Internal medicine (207R00000X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RI0008X (207RI0008X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-10-21
- NPI last updated
- 2020-11-16
- NPI record certified
- 2020-11-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1601 Esplanade Ste 3, Chico, CA, 95926 · 2367 Harrison Ave, Eureka, CA, 95501 · 1189 E Herndon Ave, Fresno, CA, 93720 · 1401 Spanos Ct Ste 125, Modesto, CA, 95355 · 101 Rowland Way Ste 220, Novato, CA, 94945 · 3300 Webster St Ste 202, Oakland, CA, 94609 · 795 El Camino Real, Palo Alto, CA, 94301 · 1315 Alhambra Blvd Ste 210, Sacramento, CA, 95816 · 1431 Noriega St, San Francisco, CA, 94122 · 2333 Buchanan St, San Francisco, CA, 94115 · 2340 Clay St Fl 2, San Francisco, CA, 94115 · 899 Valencia St, San Francisco, CA, 94110 · 3880 S Bascom Ave Ste 113, San Jose, CA, 95124 · 3883 Airway Dr, Santa Rosa, CA, 95403 · 990 Sonoma Ave, Santa Rosa, CA, 95404